TDAC.NASDAQTranslational Development Acquisition CORP
10-K/A: Translational Development Acquisition Corp. 2025 10-K/A Filing
Sentiment:
Annual Report Amendment
Translational Development Acquisition Corp. files Amendment No. 1 to its 2025 Form 10-K, primarily addressing controls and procedures.
Summary
- This filing is an amendment (Amendment No. 1) to the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, originally filed on March 30, 2026.
- The amendment specifically addresses comments received from the SEC regarding the original filing.
- Part II, Item 9A (Controls and Procedures) has been amended and restated in its entirety.
- Updated certifications from the Principal Executive Officer and Principal Financial Officer under Sections 302 and 906 of the Sarbanes-Oxley Act are included.
- The company states that its disclosure controls and procedures were effective as of December 31, 2025.
- Management also concluded that the company maintained effective internal control over financial reporting as of December 31, 2025, based on COSO criteria.
- No changes in internal control over financial reporting that materially affected or are likely to affect such controls occurred during the most recent fiscal quarter.
- The filing incorporates by reference numerous exhibits, including articles of association, share and warrant certificates, various agreements, and certifications.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is an amendment to correct or clarify previous disclosures, primarily concerning internal controls, rather than announcing new financial results or strategic initiatives.
Positives
- Disclosure controls and procedures were deemed effective as of December 31, 2025.
- Internal control over financial reporting was deemed effective as of December 31, 2025.
- No material changes in internal control over financial reporting occurred in the last fiscal quarter.
- The company has filed all required reports for the preceding 12 months and has been subject to filing requirements for the past 90 days.
Risks
- Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance.
- The design of disclosure controls and procedures reflects resource constraints and benefits considered relative to costs.
- Inherent limitations in all disclosure controls and procedures mean that no evaluation can provide absolute assurance of detecting all control deficiencies and instances of fraud.
- The design of disclosure controls and procedures is based partly on assumptions about future events, and there is no assurance that any design will succeed under all potential future conditions.
- Internal control over financial reporting may not prevent or detect errors or misstatements.
- Projections of the effectiveness of internal control over financial reporting to future periods are subject to the risk that controls may become inadequate due to changes in conditions or deterioration of compliance.
Future Outlook
This amendment does not contain specific forward-looking statements or guidance beyond the confirmation of the effectiveness of controls and procedures as of December 31, 2025.
Management Comments
- Management evaluated the effectiveness of disclosure controls and procedures and concluded they were effective as of December 31, 2025.
- Management assessed the effectiveness of internal control over financial reporting using COSO criteria and determined it was effective as of December 31, 2025.
- Management has disclosed to auditors and the audit committee all significant deficiencies, material weaknesses, and any fraud involving management or employees with a significant role in internal control over financial reporting.
Industry Context
StockSavvy.ai notes that this filing is an amendment to a 10-K, which is a standard annual report. The focus on controls and procedures is a common element of SEC filings, particularly when responding to regulatory comments. For SPACs (Special Purpose Acquisition Companies) like Translational Development Acquisition Corp., robust internal controls are crucial for maintaining investor confidence and ensuring compliance.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure Controls and Procedures | Evaluation of the effectiveness of disclosure controls and procedures as of December 31, 2025. | 2025-12-31 | Concluded that disclosure controls and procedures were effective, providing reasonable assurance but not absolute guarantee. |
| Internal Control Over Financial Reporting | Management's assessment of the effectiveness of internal control over financial reporting as of December 31, 2025, using COSO criteria. | 2025-12-31 | Determined that the company maintained effective internal control over financial reporting. |
| Changes in Internal Control | Disclosure regarding any changes in internal control over financial reporting during the most recent fiscal quarter. | 2025-12-31 | No changes occurred that materially affected, or are reasonably likely to materially affect, internal control over financial reporting. |
Stakeholder Impact
- Shareholders: The amendment clarifies the company's internal control environment, which is important for investor confidence and the reliability of financial reporting.
- Auditors and Audit Committee: Management has disclosed all significant deficiencies, material weaknesses, and fraud related to internal controls, facilitating oversight.
- Regulatory Bodies (SEC): The filing addresses SEC comments and ensures compliance with reporting requirements.
Next Steps
- The company has amended and restated Part II, Item 9A (Controls and Procedures) of its original Form 10-K.
- Updated certifications from the CEO and CFO have been filed.
- The company will continue to comply with SEC filing requirements.
Key Dates
| Date | Description |
|---|---|
| 2022-05-25 | Date of Promissory Note issued by Registrant to Stone Capital Partners LLC. |
| 2022-08-26 | Date of Form S-1 filing with Securities & Exchange Commission (incorporating Memorandum and Articles of Association, Securities Subscription Agreement). |
| 2024-07-10 | Date of Amended and Restated Promissory Note issued by Registrant to Stone Capital Partners LLC. |
| 2024-08-09 | Date of Second Amended and Restated Promissory Note issued by Registrant to Stone Capital Partners LLC. |
| 2024-08-14 | Date of Current Report on Form 8-K filing with Securities & Exchange Commission (incorporating Promissory Note dated August 8, 2025). |
| 2024-08-29 | Date of Amendment No. 1 to Securities Subscription Agreement between Registrant and Stone Capital Partners LLC. |
| 2024-10-15 | Date of Assignment and Novation Agreement among Registrant, Stone Capital Partners LLC and TDAC Partners LLC. |
| 2024-10-15 | Date of Novated Securities Subscription Agreement between Registrant and TDAC Partners LLC. |
| 2024-10-22 | Date of Form S-1 filing with Securities & Exchange Commission (incorporating Amended and Restated Promissory Note, Second Amended and Restated Promissory Note, Amendment No. 1 to Securities Subscription Agreement, Assignment and Novation Agreement, Novated Securities Subscription Agreement). |
| 2024-11-20 | Date of Form S-1/A filing with Securities & Exchange Commission (incorporating Specimen Unit Certificate, Specimen Class A Ordinary Share Certificate, Specimen Warrant Certificate, Code of Ethics). |
| 2024-12-23 | Date of Warrant Agreement between the Company and Continental Stock Transfer & Trust Company. |
| 2024-12-23 | Date of Letter Agreement among the Company, its officers and directors and the Sponsor. |
| 2024-12-23 | Date of Investment Management Trust Account Agreement between the Company and Continental Stock Transfer & Trust Company. |
| 2024-12-23 | Date of Registration Rights Agreement among the Company and certain security holders. |
| 2024-12-23 | Date of Private Placement Warrants Purchase Agreement between the Company and the Sponsor. |
| 2024-12-23 | Date of Private Placement Warrants Purchase Agreement between the Company and the Underwriter. |
| 2024-12-23 | Date of Administrative Services Agreement between the Company and the Sponsor. |
| 2024-12-27 | Date of Current Report on Form 8-K filing with Securities & Exchange Commission (incorporating Amended and Restated Memorandum and Articles of Association, Warrant Agreement, Letter Agreement, Investment Management Trust Account Agreement, Registration Rights Agreement, Private Placement Warrants Purchase Agreements, Administrative Services Agreement). |
| 2025-03-31 | Date of Annual Report on Form 10-K filing with Securities & Exchange Commission (incorporating Description of the Registrants Securities, Insider Trading Compliance Policy and Procedures, Subsidiaries of the Registrant, Policy For Recovery of Erroneously Awarded Compensation). |
| 2025-12-31 | Fiscal year end date for the Annual Report on Form 10-K. |
| 2026-03-30 | Original filing date of the Annual Report on Form 10-K for the year ended December 31, 2025. |
| 2026-04-30 | Date of SEC comment letter received by the Company. |
| 2026-05-06 | Date of this Amendment No. 1 on Form 10-K/A filing and certifications. |
Keywords
10-K/A, Amendment, Annual Report, SEC Filing, Translational Development Acquisition Corp., Controls and Procedures, Internal Control, Sarbanes-Oxley Act, Disclosure Controls, Financial Reporting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.